Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus

R. Berria, L. Glass, A. Mahankali, Y. Miyazaki, A. Monroy, E. De Filippis, K. Cusi, E. Cersosimo, R. A. DeFronzo, A. Gastaldelli

Research output: Contribution to journalArticlepeer-review

71 Scopus citations

Fingerprint

Dive into the research topics of 'Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in type II diabetes mellitus'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Biochemistry, Genetics and Molecular Biology

Physics

Pharmacology, Toxicology and Pharmaceutical Science